NFL Biosciences SA (EPA:ALNFL)
France
· Delayed Price · Currency is EUR 1.046
+0.006 (0.58%)
Apr 28, 2026, 5:14 PM CET
NFL Biosciences Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Operating Revenue | 0 | - | - | - | - | Upgrade
|
| Other Revenue | - | 0 | 0.2 | 0 | 0 | Upgrade
|
| Revenue | 0 | 0 | 0.2 | 0 | 0 | Upgrade
|
| Revenue Growth (YoY) | 308.70% | -99.98% | 909040.91% | -43.59% | 1200.00% | Upgrade
|
| Cost of Revenue | - | 1.55 | 3.48 | 2.24 | 0.53 | Upgrade
|
| Gross Profit | 0 | -1.55 | -3.28 | -2.24 | -0.53 | Upgrade
|
| Selling, General & Admin | - | 1.07 | 0.78 | 0.72 | 0.28 | Upgrade
|
| Other Operating Expenses | 3.87 | 0.11 | 0.12 | 0.07 | 0.05 | Upgrade
|
| Operating Expenses | 3.87 | 1.24 | 0.95 | 0.85 | 0.37 | Upgrade
|
| Operating Income | -3.87 | -2.79 | -4.23 | -3.08 | -0.9 | Upgrade
|
| Interest Expense | - | -0 | -0.01 | -0 | -0 | Upgrade
|
| Interest & Investment Income | 0.01 | 0.07 | 0.09 | - | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0 | -0 | 0 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 1.08 | 0.01 | 0.03 | 0.18 | -0.22 | Upgrade
|
| EBT Excluding Unusual Items | -2.78 | -2.72 | -4.11 | -2.9 | -1.12 | Upgrade
|
| Other Unusual Items | - | - | - | 0.04 | - | Upgrade
|
| Pretax Income | -2.78 | -2.72 | -4.11 | -2.86 | -1.12 | Upgrade
|
| Income Tax Expense | 0.54 | -0.64 | -0.37 | -0.42 | -0.14 | Upgrade
|
| Net Income | -3.32 | -2.08 | -3.75 | -2.44 | -0.98 | Upgrade
|
| Net Income to Common | -3.32 | -2.08 | -3.75 | -2.44 | -0.98 | Upgrade
|
| Shares Outstanding (Basic) | - | 10 | 8 | 5 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | - | 10 | 8 | 5 | 5 | Upgrade
|
| Shares Change (YoY) | - | 23.79% | 55.89% | - | - | Upgrade
|
| EPS (Basic) | - | -0.21 | -0.46 | -0.47 | -0.19 | Upgrade
|
| EPS (Diluted) | - | -0.21 | -0.46 | -0.47 | -0.19 | Upgrade
|
| Gross Margin | 100.00% | - | - | - | - | Upgrade
|
| Operating Margin | -2059909.04% | -6065415.22% | -2115.09% | -14014404.54% | -2312479.49% | Upgrade
|
| Profit Margin | -1764876.06% | -4523563.04% | -1872.63% | -11106745.46% | -2508315.38% | Upgrade
|
| EBITDA | - | -2.72 | -4.17 | -3.03 | -0.86 | Upgrade
|
| D&A For EBITDA | - | 0.07 | 0.06 | 0.05 | 0.04 | Upgrade
|
| EBIT | -3.87 | -2.79 | -4.23 | -3.08 | -0.9 | Upgrade
|
| Revenue as Reported | - | 0 | 0.2 | 0 | 0 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.